中文摘要：

目的：通过测定肺癌患者血小板源性CD40、CD40配体（CD40L）、CD62P的表达水平，探讨血小板源性CD40/CD40L在肺癌外周血中的表达及其临床意义。方法体外分离肺癌患者的血小板，用二磷酸腺苷（ADP）体外诱导前后采用流式细胞仪对其表面表达的CD40、CD40L、CD62P进行测定，并与健康人作比较。结果（1）ADP诱导前，肺癌组血小板源性CD40、CD40L、CD62P表达水平明显高于对照组（P均〈0.01）。ADP诱导后，肺癌组血小板源性CD40、CD62P表达水平明显高于对照组（P均〈0.01）（2）ADP诱导前后，不同病理类型肺癌患者血小板源性CD40、CD40L、CD62P表达水平的差异均无统计学意义（P均〉0.05）。（3）ADP诱导前后，有远处转移患者血小板源性CD40L、CD62P表达水平明显高于无远处转移患者（P〈0.05）。结论（1）肺癌患者血小板源性CD62P、CD40L表达水平增加，且表达水平与肺癌的进展程度相关，血小板源性CD40/CD40L系统在肺癌的发病中具有重要作用。（2）检测血小板源性CD40L、CD62P表达水平对研究肺癌的临床分期、预后判断有一定的参考价值。

英文摘要：

Objective To investigate the expressions of platelet-derived CD40、CD40 ligand（CD40L） in patients with lung cancer,and to evaluate the clinical signif icance of platelet-derived CD40/CD40L in lung cancer.Methods：Platelets were isolated from patients with lung cancer and normal subjects.The expression rates of platelet-derived CD40、CD40L、CD62P were measured by flow cytometry before and after adenosine diphosphate（ADP） inducing in vitro. Results （1） The expression of platelet-derived CD40、CD40L、CD62P were significantly increased in patients with lung cancer as compared with normal volunteers before induced by ADP（P〈0.01）.After induced by ADP,the expression of CD40、CD62P in patients were significantly higher than those of normal volunteers（P〈0.01）.（2） Before and after induced by ADP,the expression of platelet-derived CD40、CD40L、CD62P showed no statistically significant difference among all pathological types of patients with lung cancer（P〉0.05）.（3） Before and after induced by ADP,The expression of platelet-derived CD40L and CD62P were higher in the patients with metastasis than those of without metastasis（P〈0.05）.Conclusions （1）These results suggested that there were high levels expression of platelet-derived CD40L、CD62P in patients with lung cancer.Therefore the levels of them were correlated with the stages of lung cancer.The system of platelet-derived CD40/CD40L might have a potent effect in pathogenesis of lung cancer.（2） Measurement of platelet-derived CD40L、CD62P may therefore provide a tool for monitoring the clinical course of lung cancer.